INN Interferon beta-1b

Infibeta® is used for the treatment of multiple sclerosis. It allows the reduction in the activity of the disease and the frequency of exacerbations significantly. Infibeta® was launched onto the Russian market in 2011. Also approved in Kazakhstan.

- The most complete indications among the first-line therapy of multiple sclerosis.

- proven effectiveness in slowing the rate of progression of multiple sclerosis.

- favorable safety profile and good portability